Intracoronary Radiation Therapy Using Re-188 after percutaneous Coronary Angioplasty.
- Author:
Dong Soo LEE
;
Myoung Mook LEE
;
In Ho CHAE
- Publication Type:Original Article ; Clinical Trial
- Keywords:
Intracoronary brachytherapy;
Re-188-DTPA;
Restenosis
- MeSH:
Angioplasty*;
Animals;
Brachytherapy;
Coronary Artery Disease;
Coronary Restenosis;
Coronary Stenosis;
Humans;
Isotopes;
Myocytes, Smooth Muscle;
Radiation, Ionizing
- From:Korean Journal of Nuclear Medicine
1999;33(2):228-241
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Percutaneous coronary angioplasty is well established therapeutic modality in the management of coronary artery disease. However, the high restenosis rate of 30 to 50% limits its usefulness. The principal mechanism of restenosis, ntimalhyperplasia, is the proliferative response of vessel wall to injury, which consists largely of smooth muscle cells. A large body of animal investigations and a limited number of clinical studies have established the ability of ionizing radiation to reduce neointimal proliferation and restenosis rate significantly. Human studies have been reported that intravascular radiation after first restenosis inhibits a second restenosis. Encouraged by these reports, we are also conducting a double blind, placebo-controlled, randomized trial to evaluate this new therapeutic modality in patients with coronary artery stenosis. The objective of our trial is to determine the safety and efficacy of catheter-based solutional beta emitting radioisotope system in preventing restenosis after angioplasty. This review describes the vascular brachytherapy systems and isotopes that have been utilized in the initial clinical trials performed in this area of post PTCA coronary restenosis. The results of many worldwide ongoing clinical trials will determine whether this new technology will change the future practice of vascular intervention.
